Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $37.9 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 17.03% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $145.0 million (down 39.29% YoY), while the FY2025 annual figure was $152.8 million, down 40.91% from the prior year.
• Operating Expenses was $37.9 million for Q1 2026 at Zentalis Pharmaceuticals, up from $37.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $103.9 million in Q2 2023 to a low of $33.7 million in Q3 2025.
• Historically, Operating Expenses has averaged $57.4 million across 5 years, with a median of $57.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 63.75% in 2023, then plunged 51.26% in 2025.
• A 5-year view of Operating Expenses shows it stood at $51.8 million in 2022, then jumped by 31.24% to $67.9 million in 2023, then grew by 12.94% to $76.7 million in 2024, then slumped by 51.26% to $37.4 million in 2025, then increased by 1.24% to $37.9 million in 2026.
• The last three Operating Expenses figures came in at $37.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.